Targeting PD-1/PD-L1 in Advanced Thyroid Cancer: Therapeutic Efficacy, Predictive Biomarkers, and Clinical Challenges

AuthorMaziar Motiee-Langroudien
AuthorEbrahim Karimien
AuthorSaeed Sohrabpouren
AuthorKeyvan Aghazadehen
AuthorFarrokh Heidarien
AuthorMohammad Rasoul Ghadamien
OrcidMaziar Motiee-Langroudi [0000-0001-5836-8973]en
OrcidEbrahim Karimi [0000-0001-5356-1440]en
OrcidSaeed Sohrabpour [0000-0002-3204-7116]en
OrcidKeyvan Aghazadeh [0000-0001-8349-9473]en
OrcidFarrokh Heidari [0000-0002-6904-5691]en
OrcidMohammad Rasoul Ghadami [0000-0002-2403-4649]en
Accessioned Date2026-11-14T07:59:33Z
Issued Date2026-09-30en
AbstractContext: Thyroid cancer is the most common endocrine malignancy and generally has a favorable prognosis. However, aggressive subtypes and advanced radioactive iodine-refractory disease remain associated with limited therapeutic options and poor outcomes. The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has emerged as an important regulator of immune escape and a potential therapeutic target in advanced thyroid cancer. Evidence Acquisition: This narrative review examines evidence on PD-1/PD-L1 pathway biology, interactions between this pathway and the thyroid tumor immune microenvironment, molecular regulation, clinical significance, therapeutic applications, mechanisms of resistance, and future perspectives. Results: The PD-1/PD-L1 axis promotes immune evasion by suppressing T-cell activation, driving T-cell exhaustion, and establishing an immunosuppressive tumor microenvironment. PD-L1 expression is detectable across thyroid cancer subtypes, with the highest frequency reported in poorly differentiated and anaplastic carcinomas. The BRAF V600E mutation, mitogen-activated protein kinase pathway activation, PI3K/AKT signaling, inflammatory cytokines, and hypoxia contribute to PD-L1 regulation. Clinical responses to checkpoint blockade are heterogeneous, and the absence of validated predictive biomarkers remains a major obstacle. PD-L1 expression alone is insufficient for reliable patient selection. Conclusions: Targeting the PD-1/PD-L1 pathway offers therapeutic potential for selected patients with advanced thyroid cancer. Further progress requires integrated biomarker strategies that combine tumor genomics, immune profiling, and microenvironmental characteristics, as well as a better understanding of resistance mechanisms and validation in thyroid-specific clinical trials.en
DOIhttps://doi.org/10.5812/jkums-176099en
URIhttps://brieflands.com/journals/jkums/articles/176099en
KeywordThyroid Canceren
KeywordPD-1en
KeywordPD-L1en
KeywordCancer Immunotherapyen
PublisherBrieflandsen
TitleTargeting PD-1/PD-L1 in Advanced Thyroid Cancer: Therapeutic Efficacy, Predictive Biomarkers, and Clinical Challengesen
TypeReview Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
jkums-30-3-176099-publish-pdf.pdf
Size:
455.13 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF